Henry Schein makes advance in ‘particularly attractive’ CGM market 

MELVILLE, N.Y. – The combination of Henry Schein’s distribution capabilities with Acentus’ technology expertise will pack a one-two punch as they position themselves for future growth in the competitive diabetes market, the companies say.

Henry Schein closed recently on its acquisition of the Tampa, Fla.-based Acentus, a national supplier specializing in CGMs, in a deal that broadened its portfolio of home medical supply products.

“Acentus really enhances and integrates well with our home solutions platform by both expanding our offerings to our customers and providing exceptional service that’s integral to everything we do at Henry Schein,” said Adam Bries, vice president & general manager, Home Solutions at Henry Schein. “It was important for us to invest in a company with strong assets and a strong leadership team that could help us accelerate in this market.”

Along with its previous acquisitions of Prism Medical Products in 2021 and Shield Healthcare and Mini Pharmacy in 2023, Henry Schein now expects its home medical supply platform to have annual revenue of about $350 million 

Post-acquisition, Acentus co-founder and CEO Todd Cianfrocca, who, along with Acentus co-founders Brett Carroll, Greg Duvall and Julio Valdivia, will join Henry Schein, says the company has zeroed in on patient retention and developing a proprietary tech stack to keep patients happy and engaged, backed by a well-equipped field sales team and a smooth operations process.

“There’s an information gap a lot of the time from the clinician level to the supplier level and we’ve been successful in filling that gap,” he said. “And then, our focus – we do one thing, and we do it right, which is CGM. We know the category and we know all the nuances associated with it and we’ve got relationship with the manufacturing partners.”

Acentus, for its part, liked what it saw with Henry Schein in terms of its employee-centric culture and a broad payer portfolio, says Cianfrocca.

Both companies say they are excited about the future.

“It’s no secret that the CGM space is particularly attractive right now,” said Bries. “Most importantly though, CGMs are vital for people with diabetes in managing their overall health. As we advance our continuum of care delivery model, we will continue to invest in the home medical supply market to ensure we meet the needs of all our customers.”

• Related: Henry Schein receives funding from KKR.
• Related: CGMs spur ‘broader push’ from buyers.